|Bid||35.61 x 1200|
|Ask||35.67 x 800|
|Day's range||33.84 - 35.90|
|52-week range||11.65 - 75.00|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||12 May 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||34.33|
Gilead's stock has posted consistent growth this year as a result of its ambitious antiviral drug development program for COVID-19. With the preliminary publication of favorable clinical trial results for Gilead's remdesivir antiviral, the company cemented its earlier growth for the short term. On Thursday, Roche revealed that it was testing Gilead's remdesivir as part of a combination therapy for COVID-19, a move which will doubtlessly be followed by others in the coming weeks.
The company is an aggressive newcomer to the infectious-disease market and its COVID-19 programs are very promising.
These biotech companies are both infectious disease experts and are likely to remain in the forefront when it comes to coronavirus treatment.
Shares of Vir Biotechnology (NASDAQ: VIR) soared on Monday after the company announced some exciting news regarding its efforts to develop a treatment for COVID-19. Specifically, promising research findings from Vir's attempts to defeat COVID-19 were published in a paper in the journal Nature, one of the world's leading science journals. Vir's stock closed the day up by 32.1%.
Vir Biotechnology, Inc. (NASDAQ:VIR) came out with its quarterly results last week, and we wanted to see how the...
The companies plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory authorities to discuss accelerating their filing for starting the trials of the inhaled therapy. Shares of Vir Biotech climbed 4% to $29, while Alnylam's stock rose 1.6% to $131 in premarket trading.
The are currently no approved treatments or vaccine for COVID-19, the disease caused by the new coronavirus that has infected over 3.5 million and claimed nearly 247,000 lives. The companies' therapy candidate, VIR-2703, takes a new approach to potentially treating the virus by using RNA interference (RNAi) technology that targets and silences specific genetic material, blocking the production of deadly proteins that cause diseases. Alnylam specializes in developing RNAi drugs and currently has two FDA-approved drugs, Givlaari and Onpattro, for treating rare genetic diseases.
Vir Biotechnology, Inc. (Nasdaq: VIR) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) today announced the selection of a development candidate (DC) for VIR-2703 (also referred to as ALN-COV), an investigational RNAi therapeutic targeting the SARS-CoV-2 genome. The companies plan to soon meet with the U.S. Food and Drug Administration (FDA) and other regulatory authorities to discuss a potential accelerated path for filing an Investigational New Drug (IND) or IND equivalent application at or around year-end 2020, less than a year since program initiation. The companies plan to advance VIR-2703 as an inhalational formulation for the potential treatment and/or prevention of COVID-19.
Vir's shares rose as much as 34% following the news of GSK's investment, priced at $37.73 per Vir share, a 30% premium to the stock's Friday close. Vir's shares, trading at $35.60 on Monday, have more than doubled in the year up to Friday's close. Drugmakers across the globe are rushing to develop a treatment or vaccine for the fast-spreading coronavirus that has killed over 68,400 people globally.
Generation Bio and Vir Biotechnology announce a collaborative research agreement.
Given the urgent need for curing infected COVID-19 patients, let's take a look at the companies developing drugs/treatments for the same.
The Zacks Analyst Blog Highlights: Moderna, Inovio Pharmaceuticals, Vir Biotechnology and Alnylam Pharmaceuticals
Alnylam (ALNY) expands its collaboration pact with Vir Biotechnology to develop RNAi therapeutics targeting SARS-CoV-2, the virus that induces Covid-19. Stock gains.
The global coronavirus outbreak has shown no signs of slowing down, with the worldwide total of new cases topping 94,000 and claiming over 3,200 lives.